Paul Calabresis Career Development Award For Clinical Oncology

保罗·卡拉布雷西斯临床肿瘤学职业发展奖

基本信息

  • 批准号:
    8134698
  • 负责人:
  • 金额:
    $ 50万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-01 至 2012-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This proposal seeks to support and develop junior clinical investigators in therapeutic cancer research at the Albert Einstein College of Medicine, through a coordinated program of mentoring, didactic course work, collegial interdisciplinary collaboration, and research support. The leadership for this program is integrated with the Albert Einstein Cancer Center (AECC) and Einstein's Institute for Clinical and Translational Research (ICTR), and based on the major commitment of the Institution to the training and mentoring of young clinical investigators. This Paul Calabresi Scholars Program will select highly qualified clinical and translational investigators, including both MDs and PhDs, each developing their careers in patient-oriented clinical and translational research in cancer therapeutics. Didactic course work will be provided through the K30 and other programs, as needed, with an individualized course of instruction determined for each Scholar. Program oversight will be provided by the Principal Investigator, Dr. Roman Perez-Soler, Professor of Medicine and Associate Director for Clinical Research at the AECC. They will be assisted by an Advisory Committee of leaders of Einstein's cancer research programs, who will select Scholars and monitor each Scholar's progress, and a group of External Advisors formed by PI's of Calabresi Grants at other institutions. The Albert Einstein College of Medicine is ideally suited to implement this program. With its strong foundation in NIH supported investigation, it has invested heavily in building its clinical and translational research activities in cancer under the leadership of the AECC Director, Dr. David Goldman. The PI of this KI2 proposal will assist Dr. Goldman in this mission. Einstein's new Dean, Dr. Allen Spiegel, is deeply committed to clinical and translational investigation; as underscored by a comprehensive new Strategic Research Plan and the recent completion of a new research facility, the Center for Genetic and Translational Medicine. Einstein has an outstanding base of clinical and research training programs in cancer, which will provide a pool of highly qualified candidates for this program. Our primary clinical affiliate, Montefiore Medical Center, provides high quality care to a large, traditionally underserved population in the Bronx, a county of over 1.3 million residents, over 80% of whom are members of ethnic/racial underserved minorities. Given its unique combination of clinical and scientific resources, population diversity, research funding, talented trainees, experienced mentors, teaching programs, research facilities, and institutional commitment, Einstein is poised to succeed in this K12 effort.
描述(由申请人提供):该提案旨在通过指导、教学课程、学院跨学科合作和研究支持的协调计划,支持和培养阿尔伯特爱因斯坦医学院治疗性癌症研究的初级临床研究者。该项目的领导与阿尔伯特·爱因斯坦癌症中心(AECC)和爱因斯坦临床与转化研究所(ICTR)相结合,并基于该机构对年轻临床研究人员的培训和指导的主要承诺。这个Paul Calabresi学者计划将选择高素质的临床和转化研究人员,包括医学博士和博士,每个人都在以患者为导向的癌症治疗临床和转化研究方面发展他们的职业生涯。教学课程将根据需要通过K30和其他项目提供,并为每位学者确定个性化的教学课程。项目监督将由首席研究员,医学教授兼AECC临床研究副主任Roman Perez-Soler博士提供。他们将得到由爱因斯坦癌症研究项目领导人组成的咨询委员会的协助,该委员会将选择学者并监督每位学者的进展,以及由其他机构Calabresi Grants的PI组成的外部顾问小组。阿尔伯特·爱因斯坦医学院是实施这一计划的理想场所。在美国癌症研究中心主任David Goldman博士的领导下,该中心在美国国立卫生研究院支持的调查中建立了坚实的基础,在癌症临床和转化研究活动方面投入了大量资金。这个KI2提案的PI将协助戈德曼博士完成这项任务。爱因斯坦的新院长艾伦·斯皮格尔博士致力于临床和转化研究;一项全面的新战略研究计划和最近完成的一个新的研究设施——遗传和转化医学中心——都强调了这一点。爱因斯坦在癌症临床和研究培训项目方面拥有出色的基础,这将为该项目提供高素质的候选人。我们的主要临床分支机构Montefiore医疗中心为布朗克斯的大量传统服务不足的人口提供高质量的护理,布朗克斯县有130多万居民,其中80%以上是少数民族/种族服务不足的成员。鉴于其独特的临床和科学资源、人口多样性、研究资金、有才华的学员、经验丰富的导师、教学计划、研究设施和机构承诺的组合,爱因斯坦准备在K12的努力中取得成功。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROMAN PEREZ-SOLER其他文献

ROMAN PEREZ-SOLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROMAN PEREZ-SOLER', 18)}}的其他基金

Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy
吸入 DNA 去甲基化疗法治疗肺癌和支气管癌前病变
  • 批准号:
    8444289
  • 财政年份:
    2011
  • 资助金额:
    $ 50万
  • 项目类别:
Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy
吸入 DNA 去甲基化疗法治疗肺癌和支气管癌前病变
  • 批准号:
    8025833
  • 财政年份:
    2011
  • 资助金额:
    $ 50万
  • 项目类别:
Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy
吸入 DNA 去甲基化疗法治疗肺癌和支气管癌前病变
  • 批准号:
    8608497
  • 财政年份:
    2011
  • 资助金额:
    $ 50万
  • 项目类别:
Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy
吸入 DNA 去甲基化疗法治疗肺癌和支气管癌前病变
  • 批准号:
    8230467
  • 财政年份:
    2011
  • 资助金额:
    $ 50万
  • 项目类别:
Paul Calabresis Career Development Award For Clinical Oncology
保罗·卡拉布雷西斯临床肿瘤学职业发展奖
  • 批准号:
    8134997
  • 财政年份:
    2009
  • 资助金额:
    $ 50万
  • 项目类别:
Paul Calabresis Career Development Award For Clinical Oncology
保罗·卡拉布雷西斯临床肿瘤学职业发展奖
  • 批准号:
    8330960
  • 财政年份:
    2009
  • 资助金额:
    $ 50万
  • 项目类别:
Paul Calabresis Career Development Award For Clinical Oncology
保罗·卡拉布雷西斯临床肿瘤学职业发展奖
  • 批准号:
    7652693
  • 财政年份:
    2009
  • 资助金额:
    $ 50万
  • 项目类别:
Paul Calabresis Career Development Award For Clinical Oncology
保罗·卡拉布雷西斯临床肿瘤学职业发展奖
  • 批准号:
    8538231
  • 财政年份:
    2009
  • 资助金额:
    $ 50万
  • 项目类别:
Paul Calabresis Career Development Award For Clinical Oncology
保罗·卡拉布雷西斯临床肿瘤学职业发展奖
  • 批准号:
    7932162
  • 财政年份:
    2009
  • 资助金额:
    $ 50万
  • 项目类别:
Determinants of Resistance to Erlotinib in NSCLC
NSCLC 厄洛替尼耐药的决定因素
  • 批准号:
    7394407
  • 财政年份:
    2006
  • 资助金额:
    $ 50万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了